Your browser is no longer supported. Please, upgrade your browser.
Settings
NBIX Neurocrine Biosciences, Inc. daily Stock Chart
NBIX [NASD]
Neurocrine Biosciences, Inc.
Index- P/E- EPS (ttm)-2.30 Insider Own1.50% Shs Outstand89.42M Perf Week3.97%
Market Cap4.35B Forward P/E- EPS next Y-1.44 Insider Trans-19.10% Shs Float87.04M Perf Month3.33%
Income-200.20M PEG- EPS next Q-0.66 Inst Own98.10% Short Float10.05% Perf Quarter-5.97%
Sales0.00M P/S- EPS this Y-54.60% Inst Trans0.51% Short Ratio7.59 Perf Half Y25.36%
Book/sh2.83 P/B17.20 EPS next Y41.90% ROA-54.00% Target Price70.77 Perf Year-1.66%
Cash/sh2.63 P/C18.48 EPS next 5Y47.90% ROE-61.80% 52W Range37.35 - 55.38 Perf YTD25.81%
Dividend- P/FCF- EPS past 5Y-34.70% ROI-46.80% 52W High-12.13% Beta0.43
Dividend %- Quick Ratio10.20 Sales past 5Y-28.00% Gross Margin- 52W Low30.30% ATR1.57
Employees196 Current Ratio10.20 Sales Q/Q- Oper. Margin- RSI (14)56.66 Volatility3.03% 3.22%
OptionableYes Debt/Eq0.00 EPS Q/Q-302.90% Profit Margin- Rel Volume0.72 Prev Close48.69
ShortableYes LT Debt/Eq0.00 EarningsAug 02 AMC Payout- Avg Volume1.15M Price48.66
Recom1.60 SMA203.73% SMA503.04% SMA2006.73% Volume828,383 Change-0.06%
May-10-17Reiterated H.C. Wainwright Buy $100 → $130
May-05-17Initiated BofA/Merrill Buy $70
Jan-27-17Upgrade Oppenheimer Perform → Outperform
Nov-22-16Initiated Oppenheimer Perform
Nov-03-16Initiated Deutsche Bank Buy $65
Oct-18-16Initiated Needham Buy $62
Oct-04-16Resumed Leerink Partners Outperform $70
Jun-29-16Initiated H.C. Wainwright Buy $80
Oct-12-15Reiterated Leerink Partners Outperform $67 → $71
Oct-08-15Reiterated Piper Jaffray Overweight $86 → $96
Sep-16-15Reiterated Piper Jaffray Overweight $82 → $86
Aug-18-15Resumed Jefferies Buy
May-22-15Reiterated Piper Jaffray Overweight $56 → $64
May-22-15Reiterated Nomura Buy $61 → $69
Mar-04-15Initiated Barclays Overweight $60
Feb-10-15Reiterated Deutsche Bank Buy $35 → $45
Feb-05-15Initiated Robert W. Baird Outperform $40
Jan-09-15Reiterated Deutsche Bank Buy $25 → $35
Feb-10-14Reiterated Oppenheimer Outperform $15 → $19
Feb-07-14Reiterated MKM Partners Buy $17 → $20
Jul-25-17 08:00AM  Today's Research Reports on Stocks to Watch: Neurocrine Biosciences, Inc. and Ionis Pharmaceuticals Accesswire
Jul-21-17 09:28AM  Neurocrine Biosciences Announces the Appointment of Julie Cooke as Chief People Officer PR Newswire
Jul-06-17 09:28AM  Edited Transcript of NBIX earnings conference call or presentation 9-May-17 9:00pm GMT Thomson Reuters StreetEvents
Jul-05-17 08:26AM  Why Neurocrine is charging twice as much for its new drug as it said it would MarketWatch
Jul-04-17 08:25AM  Bayer Starts Phase III Study for Uterine Fibroids' Candidate Zacks
Jul-03-17 09:01AM  Neurocrine Biosciences: Ingrezza, Collaborations, Ratings Market Realist
Jun-09-17 01:00PM  Neurocrine Biosciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference PR Newswire
Jun-02-17 09:25AM  Neurocrine Announces Presentations Related to INGREZZA® (valbenazine) Capsules at the 21st International Congress of Parkinson's Disease and Movement Disorders PR Newswire
Jun-01-17 04:18PM  Neurocrine Biosciences to Present at the Jefferies 2017 Global Healthcare Conference PR Newswire
May-31-17 12:01PM  Top Losers in the Healthcare Sector: May 2226, 2017 Market Realist
06:00AM  Biotech Musical Chairs: Who Leads Next Investopedia
May-25-17 11:30AM  NBIX: P2 Study in Tourettes Syndrome Does Not Meet Primary Endpoint; P2b Study to Start Before End of 2017 Zacks Small Cap Research
08:43AM  Biotech And Pharma Industry And Stock News Investor's Business Daily
May-24-17 04:21PM  Did Neurocrine Just Leave The Door Open For Teva In Tourette's? Investor's Business Daily -8.67%
03:34PM  Neurocrine's Phase 2 Disappointment: Why The Company's Down, But Not Out Benzinga
02:30PM  Industry News And Stocks To Watch Investor's Business Daily
09:29AM  Biotech Movers: Inovio, Neurocrine, Alnylam TheStreet.com
May-23-17 04:15PM  Nuerocrine's Tourette's syndrome drug trial fails CNBC Videos
04:01PM  Neurocrine Announces Phase II Results of VMAT2 Inhibitor INGREZZA® For Treatment of Tourette Syndrome PR Newswire
May-19-17 02:10PM  What Drug Approval Means for Neurocrine Biosciences GuruFocus.com
May-18-17 04:05PM  Neurocrine Announces INGREZZA® (valbenazine) Capsules Pharmacokinetic Profile and Long-Term Data to be Presented at the 2017 American Psychiatric Association Annual Meeting PR Newswire
May-17-17 12:00PM  AbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix at the World Congress on Endometriosis PR Newswire
May-11-17 04:00PM  NBIX: INGREZZA Launch Commences Zacks Small Cap Research
03:00PM  Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference PR Newswire
May-10-17 09:25PM  Edited Transcript of NBIX earnings conference call or presentation 9-May-17 9:00pm GMT Thomson Reuters StreetEvents
May-09-17 05:24PM  Neurocrine reports 1Q loss Associated Press
04:01PM  Neurocrine Biosciences Reports First Quarter 2017 Results PR Newswire
01:30PM  Investor Network: Neurocrine Biosciences, Inc. to Host Earnings Call Accesswire
May-03-17 01:00PM  Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2017 Results PR Newswire
May-02-17 05:04PM  Neurocrine Biosciences, Inc. Announces Closing of Offering of $517.5 Million of Convertible Senior Notes PR Newswire
May-01-17 08:51AM  Neurocrine Biosciences new drug may cost patients more than $10,000 a month, twice as much as expected MarketWatch
Apr-29-17 03:31PM  The 3 Best Pharmaceutical Stocks to Buy in 2017 Motley Fool
Apr-26-17 06:48PM  Neurocrine Biosciences, Inc. Prices $450.0 Million Convertible Senior Notes Offering PR Newswire
Apr-25-17 04:01PM  Neurocrine Announces Proposed Convertible Senior Notes Offering PR Newswire
01:44PM  Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates Benzinga
Apr-21-17 06:00AM  Neurocrine Announces INGREZZA Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology Annual Meeting PR Newswire
Apr-18-17 06:12PM  Should You Make a Bet on the Healthcare Stocks? Zacks
Apr-13-17 05:46PM  Neurocrine's Stock Up, FDA Nod for Tardive Dyskinesia Drug Zacks
05:13PM  Pharma companies are seeking a new treatment for the backlash against high drug prices MarketWatch
11:17AM  Company News for April 13, 2017 Zacks
08:15AM  Blog Coverage Neurocrine Stock Price Rocketed 25% After FDA's First Ever Approval for its Drug for the Treatment of Tardive Dyskinesia Accesswire
Apr-12-17 04:54PM  Neurocrine Avoids Suicide Warning In Teva-Rivaling Drug; Stock Pops Investor's Business Daily +24.88%
04:34PM  Biotech stock Neurocrine surges more than 22% after FDA approves first drug for movement disorder CNBC
04:11PM  HP Hits 2-Year High On Upgrade; GrubHub, Neurocrine Touted Investor's Business Daily
03:00PM  NBIX: INGREZZA Approved by the FDA Zacks Small Cap Research
02:54PM  Here's Why Neurocrine (NBIX) Stock is Soaring 24% Today Zacks
02:43PM  Neurocine Biosciences gets FDA approval for new drug CNBC Videos
01:40PM  Approval For Neurocrine's Ingrezza Was No Surprise, But Lack Of Warning Label A Big Advantage Over Teva Benzinga
12:57PM  Neurocrine Outperforms Even Bullish Estimates Of Ingrezza Approval Upside Benzinga
12:43PM  Why Neurocrine Biosciences Stock Is Soaring Higher Today Motley Fool
12:13PM  FDA Approves Neurocrine Biosciences Movement Disorder Therapy Investopedia
10:40AM  Neurocrine Biosciences Wins Big With FDA Approval 24/7 Wall St.
10:18AM  Neurocrine Biosciences Achieves Best Case Scenario With Ingrezza Approval Benzinga
10:05AM  Biotech stock Neurocrine surges more than 22% after FDA approves first drug for movement disorder CNBC
09:32AM  Biotech Movers: Neurocrine Biosciences Leaps on Drug Approval, Synergy Pharma Issued Three Patents TheStreet.com
09:11AM  Story Stocks from Briefing.com Briefing.com
Apr-11-17 08:05PM  Neurocrine Biosciences gets FDA's OK for movement disorder drug Reuters
05:37PM  Neurocrine Announces FDA Approval of INGREZZA (valbenazine) Capsules as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD) (with multimedia) PR Newswire
05:35PM  Neurocrine surges after FDA approval for neurological disorder medication MarketWatch
05:19PM  Neurocrine Biosciences Snags U.S. Approval for Movement Disorder Drug TheStreet.com
05:17PM  Neurocrine Biosciences gets FDA OK for movement disorder drug Reuters
04:52PM  Neurocrine Announces FDA Approval of INGREZZA TM (valbenazine) Capsules as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD) PR Newswire
Apr-10-17 10:48AM  AbbVie's Elagolix Meets Primary Endpoint in Phase II Study Zacks
Apr-07-17 08:00AM  AbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual Bleeding in Women with Uterine Fibroids PR Newswire
Apr-05-17 05:08PM  ETFs with exposure to Neurocrine Biosciences, Inc. : April 5, 2017 Capital Cube -5.90%
07:30AM  Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and Neurocrine Biosciences Accesswire
Apr-04-17 04:36PM  Teva Pharma, Neurocrine Do Battle Over Neurological Treatments Investor's Business Daily
Apr-03-17 08:18AM  Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : April 3, 2017 Capital Cube
Apr-02-17 11:41AM  4 Drug Stocks With Big News Coming in April Motley Fool
Mar-31-17 04:10PM  What Does Big Pharma Want To Buy? 3 Drugmakers On Merger Track
Mar-24-17 03:18PM  Setting The Stage For Neurocrine's Pending PDUFA Date, Barclays Remains Positive Benzinga
Mar-21-17 08:59AM  Neurocrine Announces American Journal of Psychiatry Publication of Positive Results from Kinect 3 Phase III Study of INGREZZA TM (valbenazine) for the Treatment of Tardive Dyskinesia PR Newswire
Mar-13-17 06:06AM  NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Other Events
Feb-18-17 01:04PM  NEUROCRINE BIOSCIENCES INC Financials
Feb-16-17 12:34PM  Neurocrine Biosciences, Inc. :NBIX-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017 Capital Cube
12:00PM  NBIX: Acquires North American Rights to ONGENTYS® For the Treatment of Parkinsons Disease Zacks Small Cap Research
Feb-15-17 03:23PM  [2/15] Today's Top 10 Long/Short Estimize Signal Scores
Feb-14-17 10:30PM  Edited Transcript of NBIX earnings conference call or presentation 14-Feb-17 10:00pm GMT Thomson Reuters StreetEvents
04:35PM  NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
04:19PM  Neurocrine reports 4Q loss
04:01PM  Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017 PR Newswire
07:07AM  Q4 2016 Neurocrine Biosciences Inc Earnings Release - After Market Close
Feb-10-17 04:33PM  NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Pri
10:18AM  Neurocrine Inks $145 Million Parkinson's Drug Deal at Investopedia
Feb-09-17 04:01PM  Neurocrine and BIAL Announce Exclusive North American Licensing Agreement for Opicapone PR Newswire
Feb-07-17 01:00PM  Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2016 Results PR Newswire
Feb-01-17 07:35AM  Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : February 1, 2017
Jan-27-17 09:46AM  Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen
07:09AM  Neurocrine Biosci upgraded by Oppenheimer
Jan-19-17 01:30PM  NBIX: Phase 2 Study of INGREZZA in Adults with Tourette Syndrome Fails to Hit Primary Endpoint
Jan-17-17 05:55PM  After hours buzz: CSX, UAL, GIMO & more at CNBC
05:28PM  Neurocrine Med Failure, Jazz Pharma Generic Rival OK Sends Both Down
04:19PM  Neurocrine Drug Fails to Reduce Tic Severity in Tourette Syndrome Patients
04:01PM  Neurocrine Announces Completion of Phase II Clinical Study of VMAT2 Inhibitor INGREZZA (valbenazine) in Adults with Tourette Syndrome PR Newswire
09:40AM  Here Are Two Market Moving Biotech Catalysts To Watch This Week at Insider Monkey
Jan-11-17 11:15AM  Neurocrine Biosciences, Inc. Value Analysis (NASDAQ:NBIX) : January 11, 2017
Jan-10-17 07:22AM  Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : January 10, 2017 -5.31%
Jan-06-17 04:32PM  NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex +6.43%
02:00PM  NBIX: AdComm Meeting for INGREZZA Cancelled by FDA
10:28AM  What Does The Panel Cancellation Mean For Neurocrine Biosciences, Inc. (NBIX)? at Insider Monkey
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, and other Indications. It has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Grigoriadis Dimitri E.Chief Research OfficerMay 23Sale53.3910,000533,900107,691May 24 04:13 PM
Lloyd-Smith MalcolmChief Regulatory OfficerMay 19Option Exercise15.454,98076,94117,997May 23 04:34 PM
Lloyd-Smith MalcolmChief Regulatory OfficerMay 19Sale54.004,980268,92013,017May 23 04:34 PM
OBrien Christopher FlintChief Medical OfficerMay 18Option Exercise6.36105,634671,915154,607May 23 04:36 PM
Lippoldt DarinChief Legal OfficerMay 18Option Exercise18.1510,000181,50023,157May 23 04:34 PM
Lloyd-Smith MalcolmChief Regulatory OfficerMay 18Option Exercise15.454,98076,94117,997May 23 04:34 PM
Lloyd-Smith MalcolmChief Regulatory OfficerMay 18Sale53.264,980265,23513,017May 23 04:34 PM
Lippoldt DarinChief Legal OfficerMay 18Sale53.2710,000532,70013,157May 23 04:34 PM
OBrien Christopher FlintChief Medical OfficerMay 18Sale53.32105,6345,632,40548,973May 23 04:36 PM
Nevinny Corinne HDirectorMay 05Sale53.985,000269,90034,603May 08 08:22 PM
Nevinny Corinne HDirectorMay 03Option Exercise3.4015,00051,00040,555May 05 01:26 PM
POPS RICHARD FDirectorMay 03Option Exercise3.4015,00051,00030,454May 05 01:27 PM
GORMAN KEVIN CHARLESChief Executive OfficerMay 02Option Exercise2.5921,73956,304354,346May 03 06:42 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 02Sale55.0010,000550,000117,691May 03 06:43 PM
GORMAN KEVIN CHARLESChief Executive OfficerMay 02Sale53.2321,7391,157,167332,607May 03 06:42 PM
Gano KyleChief Business Development OffMay 01Option Exercise2.5915,00038,85088,246May 03 06:41 PM
Gano KyleChief Business Development OffMay 01Sale54.0015,000810,00073,246May 03 06:41 PM
MOLLICA JOSEPH ADirectorApr 12Option Exercise3.4020,00068,00057,354Apr 13 05:32 PM
Lloyd-Smith MalcolmChief Regulatory OfficerApr 12Sale50.4213,065658,77413,017Apr 13 04:56 PM
OBrien Christopher FlintChief Medical OfficerApr 12Sale50.4213,065658,77448,973Apr 13 04:56 PM
Lippoldt DarinChief Legal OfficerApr 12Sale50.4213,065658,77413,157Apr 13 04:55 PM
Grigoriadis Dimitri E.Chief Research OfficerApr 12Sale50.4213,065658,774127,691Apr 13 04:54 PM
Gano KyleChief Business Development OffApr 12Sale50.4213,065658,77473,246Apr 13 04:53 PM
GORMAN KEVIN CHARLESChief Executive OfficerApr 12Sale50.4219,596988,085332,607Apr 13 04:53 PM
Bozigian Haig P.Chief Development OfficerApr 12Sale50.4213,065658,774129,601Apr 13 04:52 PM
LYONS GARY ADirectorFeb 14Option Exercise3.4015,00051,000282,066Feb 15 06:52 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 08Option Exercise2.5964,161166,177314,703Feb 08 07:37 PM
BENEVICH ERICChief Commercial OfficerFeb 07Sale44.651325,8941,222Feb 08 07:40 PM
Lippoldt DarinChief Legal OfficerFeb 07Sale44.621325,8901,222Feb 08 07:39 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 07Sale44.611165,1751,082Feb 08 07:41 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 06Sale43.1572731,3700Feb 08 07:41 PM
OBrien Christopher FlintChief Medical OfficerFeb 06Sale43.171,20652,06337,038Feb 08 07:40 PM
Lippoldt DarinChief Legal OfficerFeb 06Sale43.1382135,4100Feb 08 07:39 PM
BENEVICH ERICChief Commercial OfficerFeb 06Sale43.1182135,3930Feb 08 07:40 PM
Coughlin Timothy PChief Financial OfficerFeb 06Sale43.1496341,544137,961Feb 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 06Sale43.183,010129,972250,542Feb 08 07:37 PM
Bozigian Haig P.Chief Development OfficerFeb 06Sale43.1496341,544117,666Feb 08 07:43 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 06Sale43.1372731,356115,756Feb 08 07:44 PM
Gano KyleChief Business Development OffFeb 06Sale43.1572731,37061,311Feb 08 07:42 PM
Coughlin Timothy PChief Financial OfficerFeb 03Sale42.551,50063,825136,324Feb 06 07:19 PM
Bozigian Haig P.Chief Development OfficerFeb 03Sale42.571,37558,534116,079Feb 06 07:19 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 03Sale42.553,125132,969247,802Feb 06 07:18 PM
Gano KyleChief Business Development OffFeb 03Sale42.571,37558,53460,113Feb 06 07:18 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 03Sale42.561,37558,520114,558Feb 06 07:17 PM
OBrien Christopher FlintChief Medical OfficerFeb 03Sale42.501,50063,75035,044Feb 06 07:16 PM
RASTETTER WILLIAM HDirectorFeb 01Option Exercise2.1725,00054,25025,000Feb 02 07:29 PM
RASTETTER WILLIAM HDirectorFeb 01Sale42.2810,750454,51014,250Feb 02 07:29 PM
Coughlin Timothy PChief Financial OfficerJan 17Sale40.651,75071,138134,824Jan 18 06:45 PM
Bozigian Haig P.Chief Development OfficerJan 17Sale40.631,62566,024114,704Jan 18 06:45 PM
Gano KyleChief Business Development OffJan 17Sale40.651,62566,05658,738Jan 18 06:44 PM
GORMAN KEVIN CHARLESChief Executive OfficerJan 17Sale40.653,750152,438244,677Jan 18 06:43 PM
Grigoriadis Dimitri E.Chief Research OfficerJan 17Sale40.631,62566,024113,183Jan 18 06:41 PM
OBrien Christopher FlintChief Medical OfficerJan 17Sale40.661,75071,15533,544Jan 18 06:41 PM
OBrien Christopher FlintChief Medical OfficerJan 10Sale43.351,75075,86331,794Jan 12 07:02 PM
Grigoriadis Dimitri E.Chief Research OfficerJan 10Sale43.391,62570,509111,558Jan 12 07:02 PM
Gano KyleChief Business Development OffJan 10Sale43.371,25054,21357,113Jan 12 07:00 PM
GORMAN KEVIN CHARLESChief Executive OfficerJan 10Sale43.283,750162,300240,927Jan 12 07:01 PM
Coughlin Timothy PChief Financial OfficerJan 10Sale43.371,75075,898133,124Jan 12 06:59 PM
Bozigian Haig P.Chief Development OfficerJan 10Sale43.371,62570,476113,079Jan 12 06:59 PM
GORMAN KEVIN CHARLESPresident and CEODec 23Option Exercise2.599,10023,569237,177Dec 23 03:44 PM
OBrien Christopher FlintChief Medical OfficerNov 15Sale52.8425,0001,321,00030,044Nov 16 03:52 PM
Lloyd-Smith MalcolmChief Regulatory OfficerSep 01Option Exercise15.459,000139,0509,000Sep 02 03:26 PM
Lloyd-Smith MalcolmChief Regulatory OfficerSep 01Sale50.009,000450,0000Sep 02 03:26 PM
OBrien Christopher FlintChief Medical OfficerAug 15Sale48.7312,500609,12555,044Aug 16 06:46 PM
Nevinny Corinne HDirectorAug 08Sale48.545,000242,70025,555Aug 09 06:05 PM